Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash.
Founded 20 years ago, Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.
Thermo Fisher executive vice-president Michel Lagarde said: “The addition of their manufacturing capabilities in Europe complements our four development and manufacturing sites in North America.
“In addition, they bring an incredibly talented team with more than two decades of experience across a broad range of viral vectors.
“The combination will benefit our global customers seeking support and capacity in the region as well as European customers bringing new medicines to patients inside and outside of Europe.”
The viral vector manufacturing business offers over 7,000m² of advanced clinical and commercial manufacturing capacity.
With two locations in Seneffe and Gosselies, Henogen has around 400 employees with extensive operational and technical proficiency in various viral vector classes.
Novasep president and CEO Michel Spagnol said: “Our diverse customer base will benefit from the combination of our viral vector services capabilities with the scale and capabilities of Thermo Fisher.
